Reason for request
Inclusion on list of products reimbursed by National Insurance and for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of FIRMAGON is substantial. |
Clinical Added Value
| no clinical added value |
In the context of the current strategy for treatment of advanced prostate cancer, with a combination of a Gn-RH analogue and an antiandrogen in the first month of treatment, FIRMAGON provides no improvement in actual benefit (IAB level V). |
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
u7hAuc8tjfHQF44U
